Richard M Stone
Richard M Stone
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow stem cell disorders characterized by dysplastic hypercellular marrows with peripheral cytopenias. The Leukemia & Lymphoma Society estimates the annual US incidence of ...
Steven Grant
Steven Grant
The concept of combining targeted agents for the treatment of acute myeloid leukemia (AML) is a relatively new but potentially promising area of investigation. A number of targeted agents may have limited single-agent activity but could sho...
Molecular characterization of AML: a significant advance or just another prognostic factor? [0.03%]
急性髓系白血病的分子特征：重要进展还是仅仅另一个预后因素？
Charles A Schiffer
Charles A Schiffer
Although there have been several major laboratory advances which have been helpful diagnostically and in the general classification of risk groups, they have not resulted in improvement in the overall outcome for patients with AML and, with...
Craig T Jordan
Craig T Jordan
Two key issues must be addressed in the discussion of targeting leukemic stem cells: (1) can the leukemic stem cell be targeted in vivo, and (2) how to assess whether the leukemic stem cell is actually being targeted. Currently several smal...
Jasmine C Wong,Michelle M Le Beau,Kevin Shannon
Jasmine C Wong
Our molecular understanding of the how tumor suppressor gene (TSG) abnormalities contribute to myeloid malignancies is relatively limited. While the NF1 and TP53 TSGs follow the Knudson two-hit paradigm and undergo biallelic inactivation, t...